Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Omtriptolide - Pharmagenesis/Pierre Fabre

Drug Profile

Omtriptolide - Pharmagenesis/Pierre Fabre

Alternative Names: F 60008; PG 49088; PG490-88Na; TriptoSar

Latest Information Update: 13 Jun 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pharmagenesis
  • Developer Pharmagenesis; Pierre Fabre
  • Class Antineoplastics; Phenanthrenes; Small molecules
  • Mechanism of Action Apoptosis stimulants; Calcium channel modulators; Immunosuppressants; T cell activation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Myeloid leukaemia; Solid tumours
  • Discontinued Graft-versus-host disease

Most Recent Events

  • 13 Jun 2018 Phase I development in Solid tumours and Myeloid leukaemia is ongoing in USA and France respectively (Pharmagenesis pipeline, June 2018)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours in USA (IV, Injection)
  • 19 Oct 2015 Phase-I development is ongoing in Solid tumours
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top